You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,921,222

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,921,222

Title:	Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
Abstract:	The present invention provides methods for the treatment of lung cancer patients, especially NSCLC with SCC or PLC using a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab. In addition, the present invention provides methods for identification or selection of lung cancer patients for the treatment with a drug against EGFR, such as an anti-EGFR antibody treatment, e.g., cetuximab based on histological determinations.
Inventor(s):	Li; Henry Qixiang (Carlsbad, CA), Yang; Mengmeng (Beijing, CN)
Assignee:	CROWN BIOSCIENCE, INC. (TAICANG) (Jiangsu Province, CN)
Application Number:	14/418,684
Patent Claims:	1. A method for treating lung cancer in a patient based on histology of the lung cancer in the patient, wherein the lung cancer is Non-small cell lung cancer (NSCLC), consisting of administering to the patient an effective amount of a drug against epidermal growth factor receptor (EGFR), wherein the drug is cetuximab, and wherein the patient having NSCLC is identified to have squamous cell carcinoma (SCC) or pleiomorphic carcinoma (PLC), but not adenocarcinoma (ADC) or large cell carcinoma (LCC), and wherein the patient is of Asian descent. 2. A method for treating lung cancer in a patient based on histology of the lung cancer in the patient, wherein the lung cancer is Non-small cell lung cancer (NSCLC), consisting of determining the histology of the lung cancer, and administering to a patient identified to have squamous cell carcinoma (SCC) or pleiomorphic carcinoma (PLC), but not adenocarcinoma (ADC) or large cell carcinoma (LCC) a drug against epidermal growth factor receptor (EGFR), wherein the drug is cetuximab, and wherein the patient is of Asian descent.

Details for Patent 9,921,222

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2032-07-31
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2032-07-31
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.